uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
1. Four-year results of Hemgenix show long-term efficacy and safety. 2. Hemgenix maintains elevated factor IX levels, enhancing bleed protection. 3. 94% of patients were free from routine prophylaxis after four years. 4. No serious adverse events were reported related to treatment. 5. QURE stock is currently down 5.95% at $15.25.